Plan B® One-Step Emergency Contraception Now Available At U.S. Pharmacies

New Single-dose Formulation Now OTC for Consumers 17 and Older

Plan B® One-Step Resources & Multimedia

* Plan B® Online Press Room
* Plan B® One-Step Fact Sheet
* Plan B® One-Step Product Images (High Res) (Low Res)
* Plan B® Video/B-Roll (WMV)

News Facts

* Plan B® One-Step, a one-pill emergency contraceptive, is currently available
at U.S. retail pharmacies
* Plan B® One-Step helps prevent unintended pregnancy after unprotected sex or
contraceptive failure
* Plan B® One-Step is available over-the-counter (OTC) for consumers age 17 or
older and available by prescription for women younger than age 17New Single-dose
Formulation Now OTC for Consumers 17 and Older

NORTH WALES, Pa.--(Business Wire)--
Teva Women`s Health, Inc. announced today that its Plan B® One-Step
(levonorgestrel) tablet, 1.5 mg emergency contraceptive is now available at
licensed U.S. retail pharmacies. Approved by the U.S. Food and Drug
Administration (FDA) on July 10, Plan B® One-Step can help prevent an unintended
pregnancy after unprotected sex or contraceptive failure with just one pill in
one dose.

Plan B® One-Step (www.PlanBOneStep.com) is available over-the-counter (OTC) at
the pharmacy for consumers age 17 or older with government-issued proof-of-age
identification. Women younger than age 17 will require a prescription to
purchase Plan B® One-Step.

"Emergency contraception is more effective the sooner it`s taken, and Plan B®
One-Step allows women to act quickly after the unexpected happens because it`s
only one pill that`s taken in one dose," comments Amy Niemann, General Manager,
Senior Vice President of Teva Women`s Health.

"Since the FDA expanded OTC access to those 17 and older, more women now have
access to Plan B® One-Step when they need it," notes Dr. Kathy Besinque, PharmD,
Associate Professor of Clinical Pharmacy, University of Southern California
School of Pharmacy. "It`s important to remember that emergency contraception is
sold from behind the pharmacy counter. The Plan B® One-Step web site has a
helpful tool that facilitates a private purchase at the pharmacy-just hand the
Patient Request Card to the pharmacist and you don`t have to say a word."

Visit www.PlanBOneStep.com to download the Plan B® One-Step Patient Request
Card.

About Plan B® One-Step

When taken as directed, within 72 hours (3 days) of unprotected sex or
contraceptive failure, Plan B® One-Step is highly effective in reducing the
chance of pregnancy. About seven out of eight women who would have gotten
pregnant will not become pregnant after taking it. Plan B® One-Step should be
taken as soon as possible after unprotected sex-the sooner it is taken, the more
effective it will be. Plan B® One-Step will not work if a woman is already
pregnant and it will not terminate an existing pregnancy.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top
20 pharmaceutical companies in the world and is the world's leading generic
pharmaceutical company. The Company develops, manufactures and markets generic
and innovative human pharmaceuticals and active pharmaceutical ingredients, as
well as animal health pharmaceutical products. Over 80 percent of Teva's sales
are in North America and Europe.

Important Safety Information

PLAN B® ONE-STEP IS INTENDED TO PREVENT PREGNANCY AFTER KNOWN OR SUSPECTED
CONTRACEPTIVE FAILURE OR UNPROTECTED INTERCOURSE.

Plan B® One-Step isn`t effective if you`re already pregnant, and it won`t
terminate an existing pregnancy. Plan B® One-Step doesn`t protect against HIV
and other sexually transmitted diseases (STDs). Side effects may include changes
in your period, nausea, lower abdominal pain, fatigue, headache, or dizziness.
If your period is more than a week late, you may be pregnant. If you have severe
abdominal pain, you may have an ectopic pregnancy, and should get immediate
medical help. Important product information is available on
www.PlanBOneStep.com, by calling1-800-330-1271, or by speaking to your
pharmacist. You are encouraged to report negative side effects of prescription
drugs to the FDA at fda.gov/medwatch or call 1-800-FDA-1088.

Teva`s Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements are based on
management's current beliefs and expectations and involve a number of known and
unknown risks and uncertainties that could cause our future results, performance
or achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include risks
relating to: our ability to successfully develop and commercialize additional
pharmaceutical products, the introduction of competing generic equivalents, the
extent to which we may obtain U.S. market exclusivity for certain of our new
generic products and regulatory changes that may prevent us from utilizing
exclusivity periods, potential liability for sales of generic products prior to
a final resolution of outstanding patent litigation, including that relating to
the generic versions of Neurontin, Lotrel, Protonix and Ortho Tri-Cyclen Lo, the
current economic conditions, competition from brand-name companies that are
under increased pressure to counter generic products, or competitors that seek
to delay the introduction of generic products, the effects of competition on our
innovative products, especially Copaxone sales, dependence on the effectiveness
of our patents and other protections for innovative products, the impact of
consolidation of our distributors and customers, the impact of pharmaceutical
industry regulation and pending legislation that could affect the pharmaceutical
industry, our ability to achieve expected results though our innovative R&D
efforts, the difficulty of predicting U.S. Food and Drug Administration,
European Medicines Agency and other regulatory authority approvals, the
uncertainty surrounding the legislative and regulatory pathway for the
registration and approval of biotechnology-based products, the regulatory
environment and changes in the health policies and structures of various
countries, supply interruptions or delays that could result from the complex
manufacturing of our products and our global supply chain, our ability to
successfully identify, consummate and integrate acquisitions, including the
integration of BarrPharmaceuticals, Inc., the potential exposure to product
liability claims to the extent not covered by insurance, our exposure to
fluctuations in currency, exchange and interest rates, significant operations
worldwide that may be adversely affected by terrorism, political or economical
instability or major hostilities, our ability to enter into patent litigation
settlements and the intensified scrutiny by the U.S. government, the termination
or expiration of governmental programs and tax benefits, impairment of
intangible assets and goodwill, environmental risks, and other factors that are
discussed in this report and in our other filings with the U.S. Securities and
Exchange Commission ("SEC").

Plan B® is a registered trademark of Women`s Capital Corporation, a subsidiary
of Duramed Pharmaceuticals, Inc.

Tags: PlanB, Plan B One-Step, Contraceptives, Emergency Contraceptive, Women`s
Health, Pregnancy, Birth Control, Teva Women`s Health, Teva Pharmaceuticals,
Morning After Pill

Teva Pharmaceuticals
Denise Bradley, 215-591-8974
denise.bradley@tevausa.com

Copyright Business Wire 2009